CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming R&D Day, including a live video stream, on the Investors section of the company’s website, www.alnylam.com, on the morning of December 16, 2016.
Alnylam management and leading physicians will discuss development candidates from the company’s RNAi therapeutics pipeline. The event will include presentations from the following guest speakers:
Ole Suhr, M.D., Ph.D.
Chief Physician and Gastroenterologist at the Department of Medicine, and Head of the Amyloid team at the Umeå University Hospital
Robert Desnick, M.D., Ph.D.
Dean for Genetic & Genomic Medicine, Professor and Chair Emeritus at the Icahn School of Medicine at Mount Sinai
John Pasi, MB, ChB, Ph.D., FRCP, FRCPath, FRCPCH
Professor of Haemostasis and Thrombosis and Consultant Haematologist at Barts and the London School of Medicine and Dentistry, Queen Mary, University of London
The meeting will be held on Friday, December 16, 2016 from 8:00 a.m. to 12:00 p.m. ET at the Westin New York at Times Square in New York City. A replay will be available on the Alnylam website within 48 hours after the event.
About Alnylam Pharmaceuticals
Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines. Alnylam’s pipeline of investigational RNAi therapeutics is focused in 3 Strategic Therapeutic Areas (STArs): Genetic Medicines, with a broad pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases; and Hepatic Infectious Disease, with a pipeline of RNAi therapeutics that address the major global health challenges of hepatic infectious diseases. In early 2015, Alnylam launched its “Alnylam 2020” guidance for the advancement and commercialization of RNAi therapeutics as a whole new class of innovative medicines. Specifically, by the end of 2020, Alnylam expects to achieve a company profile with 3 marketed products, 10 RNAi therapeutic clinical programs – including 4 in late stages of development – across its 3 STArs. The company’s demonstrated commitment to RNAi therapeutics has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, Biogen, Roche, Takeda, Kyowa Hakko Kirin, Cubist, GlaxoSmithKline, Ascletis, Monsanto, The Medicines Company, and Sanofi Genzyme. In addition, Alnylam holds an equity position in Regulus Therapeutics Inc., a company focused on discovery, development, and commercialization of microRNA therapeutics. Alnylam scientists and collaborators have published their research on RNAi therapeutics in over 200 peer-reviewed papers, including many in the world’s top scientific journals such as Nature, Nature Medicine, Nature Biotechnology, Cell, New England Journal of Medicine, and The Lancet. Founded in 2002, Alnylam maintains headquarters in Cambridge, Massachusetts. For more information about Alnylam’s pipeline of investigational RNAi therapeutics, please visit www.alnylam.com.